InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs

Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs

Shane Gleason, current General Manager of North America & VP of Global Marketing, promoted to Chief Commercial Officer

Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

TEL AVIV, Israel and MIAMI, Oct. 03, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced senior leadership additions and changes intended to support the company’s commercial growth initiatives, including potential approval of the CGuard Prime stent platform in the U.S., development of new stent delivery systems, and growth in existing approved territories outside of the U.S.

The company announced today that it has hired Patrick Verta, MD, as Executive Vice President of Clinical and Medical Affairs and Cheryl Tal as Vice President of Quality Assurance and Regulatory Affairs. In addition, Shane Gleason, who previously served as InspireMD’s General Manager of North America and VP of Global Marketing, has been promoted to Chief Commercial Officer.

Marvin Slosman, Chief Executive Officer of InspireMD, stated, “As we build toward growing our business and leadership of carotid revascularization solutions and prepare for the potential approval of the CGuard Prime carotid stent platform in the U.S., we continue to expand our leadership team to keep pace with our advancing business needs. We are attracting top-tier talent with highly relevant expertise in the field of vascular interventions capable of providing the next-level leadership needed to fully capitalize on our rapidly expanding potential.”

“Patrick adds tremendous experience in the carotid field having supported much of the clinical advancement over the past 20 years, and he brings an impeccable reputation amongst the Key Opinion Leader (KOL), medical and regulatory communities. Leveraging the superior clinical data of CGuard and establishing a new standard by which clinical and patient outcomes are measured will continue to be a priority for our company. Additionally, as we advance our CGuard Prime stent platform with its enhanced CAS delivery system, develop a TCAR neuro protection system, and commence focus on the acute stroke segment, we will look to Patrick to shepherd our clinical and medical functions through each of these strategic pathways.